Montelukast sodium (Synonyms: MK0476)

Name: Montelukast sodium
Brand: MedChemExpress
SKU: HY-13315
Rating: 5.0 (14 reviews)

Cat. No.: HY-13315 Purity: 99.84%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research.

For research use only. We do not sell to patients.

CAS No. : 151767-02-1

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Montelukast sodium:

14 Publications Citing Use of MCE Montelukast sodium

In Vivo Efficacy Study

Bio/Physico-chemical Assay

Flow Cytometry

: Montelukast sodium purchased from MedChemExpress. Usage Cited in: Environ Pollut. 2026 May 1:396:127849.; Effect of Montelukast (Mon) (500 μM) on the metabolic inhibition rate of tetraconazole enantiomers in the in vitro incubation mixtures with HLMs.

: Montelukast sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):3177. [Abstract]; Schematic diagram of subcutaneous tumor treatment on C57BL/6 mice and representative images of Montelukast (5 mg/kg; i.p.; 7-26 d) on day 26.

: Montelukast sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):3177. [Abstract]; Tumor growth of LTP-C9 with overexpression of PDHA1 WT was observed in C57BL/6 mice treated with Montelukast (5 mg/kg; i.p.; 7-26 d).

: Montelukast sodium purchased from MedChemExpress. Usage Cited in: SSRN. 2024 Oct 29.; Montelukast (M) (2.5-5.0 mg/kg; i.p.; once daily for 19 weeks) reduced urine protein levels and concentrations of autoantibodies, including ANA and anti-dsDNA of MRL/Lpr mice.

: Montelukast sodium purchased from MedChemExpress. Usage Cited in: SSRN. 2024 Oct 29.; Montelukast (M) (2.5-5.0 mg/kg; i.p.; once daily for 19 weeks) decreased the percentages of ASCs, plasma cells, and plasmablasts in the spleen of MRL/Lpr mice.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Leukotriene Receptor Isoform Specific Products:

View All Isoforms

LTB₄ LTC₄/CysLT₂ LTD₄/CysLT₁ LTE₄

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

CysLT₁

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.31 μM Compound: Singulair	Antagonist activity against CysLT1 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of LTD4-induced calcium mobilization pre-incubated for 10 mins before LTD4 addition by Fluo-4 AM dye based fluorimetric assay Antagonist activity against CysLT1 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of LTD4-induced calcium mobilization pre-incubated for 10 mins before LTD4 addition by Fluo-4 AM dye based fluorimetric assay	[PMID: 26985325]
HEK293	IC₅₀	27 μM Compound: Singulair	Antagonist activity against CysLT2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of LTD4-induced calcium mobilization pre-incubated for 10 mins before LTD4 addition by Fluo-4 AM dye based fluorimetric assay Antagonist activity against CysLT2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of LTD4-induced calcium mobilization pre-incubated for 10 mins before LTD4 addition by Fluo-4 AM dye based fluorimetric assay	[PMID: 26985325]

In Vitro

Montelukast (5 μM; 1 h) inhibits APAP (Acetaminophen) (HY-66005)-induced cell damage^[1].
Montelukast (0.01-10 μM; 30 min) diminishes the 5-oxo-ETE–induced cell migration and modulates the activation of the plasmin-plasminogen system^[3].
Montelukast (10 μM; 18 h) modulates the activation of MMP-9^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[3]

Cell Line:	Eosinophils
Concentration:	0.01-10 μM
Incubation Time:	30 min
Result:	Diminished the 5-oxo-ETE–induced cell migration.

Western Blot Analysis^[3]

Cell Line:	Eosinophils
Concentration:	10 μM
Incubation Time:	18 h
Result:	Reduced the 5-oxo-ETE–boosted MMP-9 secretion.

In Vivo

Montelukast (3 mg/kg; oral gavage) protects against APAP-induced hepatotoxicity in mice^[1].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor^[2].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury^[1]
Dosage:	3 mg/kg
Administration:	Oral gavage 1 h after saline or APAP administration
Result:	Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage.

Clinical Trial

Molecular Weight

608.17

Formula

C₃₅H₃₅ClNNaO₃S

CAS No.

151767-02-1

Appearance

Solid

Color

White to off-white

SMILES

ClC1=CC2=C(C=C1)C=CC(/C=C/C3=CC([C@H](SCC4(CC(O[Na])=O)CC4)CCC5=CC=CC=C5C(C)(O)C)=CC=C3)=N2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : ≥ 50 mg/mL (82.21 mM)

DMSO : 50 mg/mL (82.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6443 mL	8.2214 mL	16.4428 mL
5 mM	0.3289 mL	1.6443 mL	3.2886 mL
10 mM	0.1644 mL	0.8221 mL	1.6443 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 1 mg/mL (1.64 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (41.11 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.84%

Select Batch:

Data Sheet (280 KB) SDS (476 KB)

COA (252 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070. [Content Brief]

[2]. William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16. [Content Brief]

[3]. Langlois A, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118(1):113-119. [Content Brief]

[4]. Khan AR, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022 Apr;59(4):780-786. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.6443 mL	8.2214 mL	16.4428 mL	41.1069 mL
	5 mM	0.3289 mL	1.6443 mL	3.2886 mL	8.2214 mL
	10 mM	0.1644 mL	0.8221 mL	1.6443 mL	4.1107 mL
	15 mM	0.1096 mL	0.5481 mL	1.0962 mL	2.7405 mL
	20 mM	0.0822 mL	0.4111 mL	0.8221 mL	2.0553 mL
	25 mM	0.0658 mL	0.3289 mL	0.6577 mL	1.6443 mL
	30 mM	0.0548 mL	0.2740 mL	0.5481 mL	1.3702 mL
	40 mM	0.0411 mL	0.2055 mL	0.4111 mL	1.0277 mL
	50 mM	0.0329 mL	0.1644 mL	0.3289 mL	0.8221 mL
	60 mM	0.0274 mL	0.1370 mL	0.2740 mL	0.6851 mL
	80 mM	0.0206 mL	0.1028 mL	0.2055 mL	0.5138 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Montelukast sodium Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Montelukast sodium (Synonyms: MK0476)

Customer Review

Other Forms of Montelukast sodium:

Montelukast sodium Related Antibodies

14 Publications Citing Use of MCE Montelukast sodium

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Leukotriene Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Montelukast sodium Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Montelukast sodium Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report